These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 36479115)

  • 1. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
    Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
    Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
    Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
    Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Jia Y; Dong X; Yang F; Zhou L; Long H
    BMC Nephrol; 2024 Sep; 25(1):298. PubMed ID: 39256647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
    Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
    Bao W; Han Q; Guan X; Wang Z; Gu M
    Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
    Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
    BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
    Lin H; Fu L; Li P; Zhu J; Xu Q; Wang Y; Mumin MA; Zhou X; Chen Y; Shu G; Yao G; Chen M; Lu J; Zhang L; Liu Y; Zhao Y; Bao J; Chen W; Luo J; Li X; Chen Z; Cao J
    J Transl Med; 2023 May; 21(1):343. PubMed ID: 37221577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a Seven-Gene Signature Associated with CD8
    Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.